0001110803-20-000011.txt : 20200129 0001110803-20-000011.hdr.sgml : 20200129 20200129160811 ACCESSION NUMBER: 0001110803-20-000011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20200129 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200129 DATE AS OF CHANGE: 20200129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ILLUMINA, INC. CENTRAL INDEX KEY: 0001110803 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 330804655 STATE OF INCORPORATION: DE FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35406 FILM NUMBER: 20558249 BUSINESS ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 8582024500 MAIL ADDRESS: STREET 1: 5200 ILLUMINA WAY CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: ILLUMINA INC DATE OF NAME CHANGE: 20000331 8-K 1 ilmn-20200129.htm 8-K ilmn-20200129
0001110803FALSE00011108032020-01-292020-01-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 29, 2020
ilmn-20200129_g1.jpg
Illumina, Inc.
(Exact name of registrant as specified in its charter)

001-35406
(Commission File Number)
Delaware 33-0804655
(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122
(Address of principal executive offices) (Zip code)

(858) 202-4500
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueILMNThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o    


TABLE OF CONTENTS





Item 2.02 Results of Operations and Financial Condition.

On January 29, 2020, Illumina, Inc. (the "Company") issued a press release announcing financial results for the fourth quarter and fiscal year ended December 29, 2019. The full text of the Company’s press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.




Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release dated January 29, 2020, announcing Illumina, Inc.’s financial results for the fourth quarter and fiscal year ended December 29, 2019.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    
 
ILLUMINA, INC.
 
Date:January 29, 2020By:  
/s/ SAM A. SAMAD
  Sam A. Samad
  Senior Vice President and Chief Financial Officer




Exhibit Index

Exhibit NumberDescription
Press release dated January 29, 2020 announcing Illumina, Inc.’s financial results for the fourth quarter and fiscal year ended December 29, 2019.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


 EX-99.1 2 a4q19earningsrelease.htm EX-99.1 Document

Investors:
Jacquie Ross, CFA
858-882-2172
ir@illumina.com
image11.jpg
Media:
Eric Endicott
858-882-6822
pr@illumina.com

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019

San Diego -- (BUSINESS WIRE) - January 29, 2020 - Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.

Fourth quarter 2019 results:

•Revenue of $953 million, a 10% increase compared to $867 million in the fourth quarter of 2018
•GAAP net income attributable to Illumina stockholders for the quarter of $239 million, or $1.61 per diluted share, compared to $210 million, or $1.41 per diluted share, for the fourth quarter of 2018
•Non-GAAP net income attributable to Illumina stockholders for the quarter of $252 million, or $1.70 per diluted share, compared to $197 million, or $1.32 per diluted share, for the fourth quarter of 2018 (see the “Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures)
•Cash flow from operations of $443 million compared to $300 million in the fourth quarter of 2018
•Free cash flow (cash flow from operations less capital expenditures) of $386 million for the quarter compared to $235 million in the fourth quarter of 2018

Gross margin in the fourth quarter of 2019 was 69.5% compared to 68.1% in the prior year period. Excluding amortization of acquired intangible assets, non-GAAP gross margin was 70.2% for the fourth quarter of 2019 compared to 69.1% in the prior year period.

Research and development (R&D) expenses for the fourth quarter of 2019 were $161 million compared to $176 million in the prior year period. Excluding restructuring charges, non-GAAP R&D expenses as a percentage of revenue were 16.8% compared to 20.3% in the prior year period.

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2019 were $233 million compared to $217 million in the prior year period. Excluding amortization of acquired intangible assets, acquisition-related expenses, and restructuring charges, non-GAAP SG&A expenses as a percentage of revenue were 22.2% compared to 24.5% in the prior year period.

Depreciation and amortization expenses were $46 million and capital expenditures for free cash flow purposes were $57 million during the fourth quarter of 2019. At the close of the quarter, the company held $3.4 billion in cash, cash equivalents and short-term investments, compared to $3.5 billion as of December 30, 2018.

Fiscal year 2019 results:

•Revenue of $3,543 million, a 6% increase compared to $3,333 million in fiscal 2018
•GAAP net income attributable to Illumina stockholders of $1,002 million, or $6.74 per diluted share, compared to $826 million, or $5.56 per diluted share, in fiscal 2018
•Non-GAAP net income attributable to Illumina stockholders of $976 million, or $6.57 per diluted share, compared to $850 million, or $5.72 per diluted share, in fiscal 2018. Non-GAAP net income excludes unrealized net gains of $66 million from mark-to-market adjustments on our strategic investments, primarily from our marketable equity securities (see the “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures)
•Cash flow from operations of $1,051 million compared to $1,142 million in fiscal 2018


•Free cash flow (cash flow from operations less capital expenditures) of $842 million, compared to $846 million in fiscal 2018

Gross margin for fiscal 2019 was 69.6% compared to 69.0% in the prior year. Excluding amortization of acquired intangible assets, non-GAAP gross margin was 70.6% for fiscal 2019 compared to 70.1% in the prior year period.

R&D expenses for fiscal 2019 were $647 million compared to $623 million in the prior year. Excluding restructuring charges, non-GAAP R&D expenses as a percentage of revenue were 18.2% compared to 18.7% in the prior year period.

SG&A expenses for fiscal 2019 were $835 million compared to $794 million in the prior year period. Excluding amortization of acquired intangible assets, acquisition-related expenses, and restructuring charges, non-GAAP SG&A expenses as a percentage of revenue were 22.0% compared to 23.6% in the prior year period.

“Illumina shipped a record 2,400 sequencing systems in 2019, including a record number of our high-throughput NovaSeq systems and mid-throughput NextSeq systems, reflecting strong demand for research and clinical sequencing,” said Francis deSouza, President and CEO. “With the launch of our most innovative system to date in the NextSeq 2000, and a growing pipeline of clinical IVD and software solutions, Illumina continues to improve the accessibility of sequencing. Almost 17 years after the first human genome was sequenced, we believe that this is the decade that genomics becomes available to cancer and genetic disease patients on a mass scale and integrates into standard of care.”

Updates since our last earnings release:

•Announced the NextSeq™ 1000 and NextSeq 2000 Sequencing Systems offering breakthrough system design, chemistry innovations and on-instrument integrated informatics for rapid secondary analysis
•Shared plans for additional product launches including TruSight™ Software Suite to enable sample-to-report for genetic disease and NovaSeq Dx to fulfill the growing interest in a Dx platform for deeper sequencing at higher throughput, and TruSight NIPT
•Partnered with Roche to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology
•Partnered with Genomics England to provide sequencing services to the United Kingdom's National Health Service to sequence 300,000 to 500,000 whole genomes by 2025
•Mutually terminated the merger agreement with Pacific Biosciences
•Filed patent infringement suits against BGI in Sweden and the United Kingdom
•Repurchased $63 million of outstanding common stock in the fourth quarter of 2019 under the previously announced share repurchase program, which had a remaining balance of approximately $226 million as of December 29, 2019

Financial outlook and guidance

The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance. Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and non-GAAP financial measures.

For fiscal 2020, the company expects year over year revenue growth in the range of 9% to 11%, and expects GAAP earnings per diluted share of $6.45 to $6.65 and non-GAAP earnings per diluted share of $6.80 to $7.00. GAAP guidance does not include any potential impact resulting from the termination of our merger agreement with Pacific Biosciences on January 2, 2020.

Quarterly conference call information

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Wednesday, January 29, 2020. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the “Company” tab at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with conference ID 2966099.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.



Statement regarding use of non-GAAP financial measures

The company reports non-GAAP results for diluted net income per share, net income, gross margins, operating expenses, operating margins, other income, and free cash flow in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company’s financial measures under GAAP include substantial charges such as amortization of acquired intangible assets, non-cash interest expense associated with the company’s convertible debt instruments that may be settled in cash, and others that are listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Additionally, non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders are key components of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2020 and our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to manufacture robust instrumentation and consumables; (v) the success of products and services competitive with our own; (vi) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (vii) the impact of recently launched or pre-announced products and services on existing products and services; (viii) our ability to further develop and commercialize our instruments and consumables, to deploy new products, services, and applications, and to expand the markets for our technology platforms; (ix) our ability to obtain regulatory clearance for our products from government agencies; (x) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xi) our ability to successfully identify and integrate acquired technologies, products, or businesses; and (xxii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

# # #


Illumina, Inc.
Condensed Consolidated Balance Sheets
(In millions)

December 29,
2019		December 30,
2018
ASSETS(unaudited)
Current assets:
Cash and cash equivalents$2,042  $1,144  
Short-term investments1,372  2,368  
Accounts receivable, net573  514  
Inventory359  386  
Prepaid expenses and other current assets105  78  
Total current assets4,451  4,490  
Property and equipment, net889  1,075  
Operating lease right-of-use assets555  —  
Goodwill824  831  
Intangible assets, net145  185  
Deferred tax assets, net64  70  
Other assets388  308  
Total assets$7,316  $6,959  
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$149  $184  
Accrued liabilities516  513  
Long-term debt, current portion—  1,107  
Total current liabilities665  1,804  
Operating lease liabilities695  —  
Long-term debt1,141  890  
Other long-term liabilities202  359  
Redeemable noncontrolling interests—  61  
Stockholders’ equity4,613  3,845  
Total liabilities and stockholders’ equity$7,316  $6,959  



Illumina, Inc.
Condensed Consolidated Statements of Income
(In millions, except per share amounts)
(unaudited)

Three Months EndedYear Ended
December 29,
2019		December 30,
2018		December 29,
2019		December 30,
2018
Revenue:
Product revenue$812  $738  $2,929  $2,749  
Service and other revenue141  129  614  584  
Total revenue953  867  3,543  3,333  
Cost of revenue:
Cost of product revenue (a)
230  198  802  738  
Cost of service and other revenue (a)
55  70  240  260  
Amortization of acquired intangible assets6  9  34  35  
Total cost of revenue291  277  1,076  1,033  
Gross profit662  590  2,467  2,300  
Operating expense:
Research and development (a)
161  176  647  623  
Selling, general and administrative (a)
233  217  835  794  
Total operating expense394  393  1,482  1,417  
Income from operations268  197  985  883  
Other income, net1  13  133  11  
Income before income taxes269  210  1,118  894  
Provision for income taxes30  12  128  112  
Consolidated net income239  198  990  782  
Add: Net loss attributable to noncontrolling interests—  12  12  44  
Net income attributable to Illumina stockholders$239  $210  $1,002  $826  
Earnings per share attributable to Illumina stockholders:
Basic$1.63  $1.43  $6.81  $5.63  
Diluted$1.61  $1.41  $6.74  $5.56  
Shares used in computing earnings per common share:
Basic147  147  147  147  
Diluted148  149  149  149  



(a) Includes stock-based compensation expense for stock-based awards:

Three Months EndedYear Ended
December 29,
2019		December 30,
2018		December 29,
2019		December 30,
2018
Cost of product revenue$5  $4  $19  $16  
Cost of service and other revenue1  —  4  3  
Research and development16  15  66  60  
Selling, general and administrative28  28  105  114  
Stock-based compensation expense before taxes (1)
$50  $47  $194  $193  
(1) Includes stock-based compensation of $1.5 million for Helix in fiscal 2019. This compares to stock-based compensation for Helix of $3.9 million in fiscal 2018, of which $1.6 million was in Q4 2018.


Illumina, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(unaudited)

Three Months EndedYear Ended
December 29,
2019		December 30,
2018		December 29,
2019		December 30,
2018
Net cash provided by operating activities (b)
$443  $300  $1,051  $1,142  
Net cash (used in) provided by investing activities(104) (349) 745  (1,813) 
Net cash (used in) provided by financing activities(115) (153) (897) 594  
Effect of exchange rate changes on cash and cash equivalents3  —  (1) (4) 
Net increase (decrease) in cash and cash equivalents227  (202) 898  (81) 
Cash and cash equivalents, beginning of period1,815  1,346  1,144  1,225  
Cash and cash equivalents, end of period$2,042  $1,144  $2,042  $1,144  
Calculation of free cash flow:
Net cash provided by operating activities (b)
$443  $300  $1,051  $1,142  
Purchases of property and equipment(57) (65) (209) (296) 
Free cash flow (a)
$386  $235  $842  $846  
(a) Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies.
(b) Net cash provided by operating activities in fiscal 2019 included an $84 million payment of the accreted debt discount related to the conversions of our 2019 Notes.


Illumina, Inc.
Results of Operations - Non-GAAP
(In millions, except per share amounts)
(unaudited)

RECONCILIATION BETWEEN GAAP AND NON-GAAP EARNINGS PER SHARE ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS:

Three Months EndedYear Ended
December 29,
2019		December 30,
2018		December 29,
2019		December 30,
2018
GAAP earnings per share attributable to Illumina stockholders - diluted$1.61  $1.41  $6.74  $5.56  
Cost of revenue (b)
0.04  0.06  0.23  0.24  
Research and development costs (b)
0.01  —  0.02  0.01  
Selling, general and administrative costs (b)
0.14  0.03  0.36  0.06  
Other expense (income), net (b)
0.08  (0.02) (0.47) 0.11  
Incremental non-GAAP tax expense (c)
(0.09) (0.01) (0.11) (0.10) 
Income tax benefit (d)
(0.09) (0.15) (0.20) (0.16) 
Non-GAAP earnings per share attributable to Illumina stockholders - diluted (a)
$1.70  $1.32  $6.57  $5.72  

RECONCILIATION BETWEEN GAAP AND NON-GAAP NET INCOME ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS:

Three Months EndedYear Ended
December 29,
2019		December 30,
2018		December 29,
2019		December 30,
2018
GAAP net income attributable to Illumina stockholders$239  $210  $1,002  $826  
Cost of revenue (b)
6  9  34  35  
Research and development costs (b)
1  —  3  1  
Selling, general and administrative costs (b)
21  5  54  9  
Other expense (income), net (b)
13  (3) (70) 17  
Incremental non-GAAP tax expense (c)
(14) (2) (16) (15) 
Income tax benefit (d)
(14) (22) (31) (23) 
Non-GAAP net income attributable to Illumina stockholders (a)
$252  $197  $976  $850  
All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders exclude the effect of the pro forma adjustments as detailed above. Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders are key components of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance.
(b) Refer to our “Itemized Reconciliation between GAAP and Non-GAAP Results of Operations as a Percent of Revenue,” below, for the components of these amounts.
(c) Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.
(d) Amounts represent tax deductions taken in excess of stock compensation cost. Amount for fiscal 2018 also includes an $11 million discrete tax expense associated with updating our 2017 estimates of the impact of U.S. Tax Reform.


Illumina, Inc.
Results of Operations - Non-GAAP (continued)
(Dollars in millions)
(unaudited)

ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:

Three Months EndedYear Ended
December 29,
2019		December 30,
2018		December 29,
2019		December 30,
2018
GAAP gross profit$662  69.5 %$590  68.1 %$2,467  69.6 %$2,300  69.0 %
Amortization of acquired intangible assets (b)
6  0.7 %9  1.0 %34  1.0 %35  1.1 %
Non-GAAP gross profit (a)
$668  70.2 %$599  69.1 %$2,501  70.6 %$2,335  70.1 %
GAAP research and development expense$161  16.9 %$176  20.3 %$647  18.3 %$623  18.7 %
Restructuring (c)
(1) (0.1)%—  —  (3) (0.1)%(1) —  
Non-GAAP research and development expense$160  16.8 %$176  20.3 %$644  18.2 %$622  18.7 %
GAAP selling, general and administrative expense$233  24.4 %$217  25.0 %$835  23.5 %$794  23.8 %
Amortization of acquired intangible assets(1) (0.1)%—  —  (2) —  (2) —  
Acquisition-related expenses (d)
(12) (1.3)%(2) (0.2)%(43) (1.2)%(2) —  
Restructuring (c)
(8) (0.8)%(3) (0.3)%(9) (0.3)%(5) (0.2)%
Non-GAAP selling, general and administrative expense$212  22.2 %$212  24.5 %$781  22.0 %$785  23.6 %
GAAP operating profit$268  28.1 %$197  22.7 %$985  27.8 %$883  26.5 %
Cost of revenue6  0.7 %9  1.0 %34  1.0 %35  1.1 %
Research and development costs1  0.1 %—  —  3  0.1 %1  —  
Selling, general and administrative costs21  2.1 %5  0.6 %54  1.5 %9  0.3 %
Non-GAAP operating profit (a)
$296  31.0 %$211  24.3 %$1,076  30.4 %$928  27.9 %
GAAP other income, net$1  0.1 %$13  1.5 %$133  3.8 %$11  0.3 %
Non-cash interest expense (e)
11  1.2 %15  1.7 %49  1.4 %41  1.2 %
Strategic investment related loss (gain), net (f)
2  0.1 %(18) (2.1)%(66) (1.9)%(24) (0.7)%
Gains on deconsolidation (g)
—  —  —  —  (54) (1.5)%—  —  
Loss on contingent value right (h)
—  —  —  —  1  —  —  —  
Non-GAAP other income, net (a)
$14  1.4 %$10  1.1 %$63  1.8 %$28  0.8 %
All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Non-GAAP gross profit, included within non-GAAP operating profit, is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of our products and services. Non-GAAP operating profit, and non-GAAP other income, net, exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance.
(b) Amounts are recorded in cost of revenue.
(c) Amounts consist primarily of employee and lease exit costs related to restructuring that occurred in 2019, 2018, and 2017.


(d) Amounts consist of expenses related to the Pacific Biosciences acquisition which was terminated on January 2, 2020.
(e) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.
(f) Amounts consist primarily of mark-to-market adjustments and impairments from our strategic investments.
(g) Amounts consist of the $39 million gain recognized as a result of the Helix deconsolidation in Q2 and the $15 million gain recorded in Q1 that resulted from the settlement of a contingency related to the deconsolidation of GRAIL in 2017.
(h) Amounts consist of mark-to-market adjustments related to our contingent value right received from Helix.



Illumina, Inc.
Reconciliation of Non-GAAP Financial Guidance
(unaudited)

Our future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the guidance set forth below. Some of the factors that could affect our financial results are stated above in this press release. More information on potential factors that could affect our financial results is included from time to time in the public reports filed with the Securities and Exchange Commission, including Form 10-K for the fiscal year ended December 30, 2018 filed with the SEC on February 11, 2019, Form 10-Q for the fiscal quarter ended March 31, 2019, Form 10-Q for the fiscal quarter ended June 30, 2019, and Form 10-Q for the fiscal quarter ended September 29, 2019. We assume no obligation to update any forward-looking statements or information.

Fiscal Year
2020
GAAP diluted earnings per share (a)$6.45 - $6.65
Amortization of acquired intangible assets0.19  
Non-cash interest expense (b)
0.28  
Incremental non-GAAP tax expense (c)
(0.12) 
Non-GAAP diluted earnings per share
$6.80 - $7.00  

(a) This guidance does not include any potential impact resulting from the termination of our merger agreement with Pacific Biosciences on January 2, 2020.
(b) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.
(c) Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed.


 EX-101.SCH 3 ilmn-20200129.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 ilmn-20200129_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 ilmn-20200129_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 ilmn-20200129_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Type Document Type Cover page. City Area Code City Area Code Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Registrant Name Entity Registrant Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Trading Symbol Trading Symbol Entity Address, State or Province Entity Address, State or Province Title of 12(b) Security Title of 12(b) Security Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 7 ilmn-20200129_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 ilmn-20200129_g1.jpg begin 644 ilmn-20200129_g1.jpg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end GRAPHIC 9 image11.jpg begin 644 image11.jpg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end XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.illumina.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ilmn-20200129.htm a4q19earningsrelease.htm ilmn-20200129.xsd ilmn-20200129_cal.xml ilmn-20200129_def.xml ilmn-20200129_lab.xml ilmn-20200129_pre.xml ilmn-20200129_g1.jpg http://xbrl.sec.gov/dei/2019-01-31 true true XML 11 ilmn-20200129_htm.xml IDEA: XBRL DOCUMENT 0001110803 2020-01-29 2020-01-29 0001110803 false 8-K 2020-01-29 Illumina, Inc. 001-35406 DE 33-0804655 5200 Illumina Way San Diego CA 92122 858 202-4500 false false false false false false Common Stock, $0.01 par value ILMN NASDAQ false 2020-01-29 2020-01-29 2020-01-29 XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover
Jan. 29, 2020
Cover page.  
Document Type 8-K
Document Period End Date Jan. 29, 2020
Entity Registrant Name Illumina, Inc.
Entity File Number 001-35406
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 33-0804655
Entity Address, Address Line One 5200 Illumina Way
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code 858
Local Phone Number 202-4500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol ILMN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001110803
Amendment Flag false
XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 15 0001110803-20-000011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001110803-20-000011-xbrl.zip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�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end JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ilmn-20200129.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "ilmn-20200129_cal.xml" ] }, "definitionLink": { "local": [ "ilmn-20200129_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "ilmn-20200129.htm" ] }, "labelLink": { "local": [ "ilmn-20200129_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ilmn-20200129_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ilmn-20200129.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ilmn", "nsuri": "http://www.illumina.com/20200129", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ilmn-20200129.htm", "contextRef": "idf0d00ce899741e68c39676c643d6f1a_D20200129-20200129", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.illumina.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ilmn-20200129.htm", "contextRef": "idf0d00ce899741e68c39676c643d6f1a_D20200129-20200129", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.illumina.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } EXCEL 17 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end